2024
Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox model
2023
Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank
Rentsch C, Garfield V, Mathur R, Eastwood S, Smeeth L, Chaturvedi N, Bhaskaran K. Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank. The Lancet Regional Health - Europe 2023, 32: 100693. PMID: 37671124, PMCID: PMC10477037, DOI: 10.1016/j.lanepe.2023.100693.Peer-Reviewed Original ResearchCoronary artery diseaseDeep vein thrombosisSex-specific riskCardiovascular diseaseUndiagnosed diabetesGlycaemic spectrumPulmonary embolismExcess riskPopulation-based cohort studyRisk of CVDAge-adjusted HRIncident cardiovascular diseaseBritish Heart FoundationSex-specific associationsUK BiobankWeight reduction strategiesStatin medicationStatin useClinical characteristicsCohort studyComposite outcomeNormal HbA1cVein thrombosisArtery diseaseHeart failureTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients
2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypesGeographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States
Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States. Scientific Reports 2022, 12: 273. PMID: 34997001, PMCID: PMC8741774, DOI: 10.1038/s41598-021-03967-5.Peer-Reviewed Original Research
2021
Trends and clinical characteristics of 57.9 million COVID-19 vaccine recipients: a federated analysis of patients’ primary care records in situ using OpenSAFELY
Curtis HJ, Inglesby P, Morton CE, MacKenna B, Green A, Hulme W, Walker AJ, Morley J, Mehrkar A, Bacon S, Hickman G, Bates C, Croker R, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson EJ, Rowan A, Fisher L, McDonald HI, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wing K, Wong AY, Forbes H, Parry J, Hester F, Harper S, O’Hanlon S, Eavis A, Jarvis R, Avramov D, Griffiths P, Fowles A, Parkes N, Douglas IJ, Evans SJ, Smeeth L, Goldacre B, . Trends and clinical characteristics of 57.9 million COVID-19 vaccine recipients: a federated analysis of patients’ primary care records in situ using OpenSAFELY. British Journal Of General Practice 2021, 72: bjgp.2021.0376. PMID: 34750106, PMCID: PMC8589463, DOI: 10.3399/bjgp.2021.0376.Peer-Reviewed Original ResearchConceptsVaccine recipientsVaccine coverageCOVID-19 vaccine recipientsFirst COVID-19 vaccinationNHS EnglandPre-existing medical conditionsPrimary care recordsLow vaccination coverageCOVID-19 vaccinationSevere mental illnessCare home residentsClinical characteristicsCohort studySecond doseVaccination coverageHome residentsMedical conditionsGeneral practiceMass vaccinationNHS dataCare recordsPatientsJoint CommitteeVaccine rolloutMental illness
2020
COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis
Boddington N, Charlett A, Elgohari S, Walker J, McDonald H, Byers C, Coughlan L, Vilaplana T, Whillock R, Sinnathamby M, Panagiotopoulos N, Letley L, MacDonald P, Vivancos R, Edeghere O, Shingleton J, Bennett E, Grint D, Strongman H, Mansfield K, Rentsch C, Minassian C, Douglas I, Mathur R, Peppa M, Cottrell S, McMenamin J, Zambon M, Ramsay M, Dabrera G, Saliba V, Bernal J. COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. Bulletin Of The World Health Organization 2020, 99: 178-189. PMID: 33716340, PMCID: PMC7941108, DOI: 10.2471/blt.20.265603.Peer-Reviewed Original ResearchConceptsProportion of COVID-19 casesPredictive value of symptomsTraining public health professionalsHealth-care seeking behaviorOccurrence of feverCase-control analysisCourse of diseaseSpecificity of symptomsShortness of breathPublic health professionalsProportion of childrenClinical presentationClinical characteristicsExposure to infectionRespiratory infectionsCases of coronavirus disease 2019Household contactsHealth professionalsBurden of COVID-19Predictive valueCase definitionCoronavirus disease 2019COVID-19 casesControl groupFeverPatterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study
Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re V, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLOS Medicine 2020, 17: e1003379. PMID: 32960880, PMCID: PMC7508372, DOI: 10.1371/journal.pmed.1003379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBlack or African AmericanClinical Laboratory TechniquesCohort StudiesCoronavirus InfectionsCOVID-19COVID-19 TestingEthnicityFemaleHispanic or LatinoHumansMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2United StatesVeteransWhite PeopleYoung AdultConceptsCOVID-19 testingRace/ethnicityCohort studyWhite individualsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionCOVID-19Large integrated healthcare systemCoronavirus 2 infectionNationwide cohort studyRetrospective cohort studyCoronavirus disease 2019Site of careIntegrated healthcare systemNon-Hispanic blacksPositive test resultsNon-Hispanic whitesClinical characteristicsMultivariable adjustmentComorbid conditionsMedication historyEthnic minority communitiesDisease 2019
2018
Non-disclosure of HIV testing history in population-based surveys: implications for estimating a UNAIDS 90-90-90 target
Rentsch C, Reniers G, Machemba R, Slaymaker E, Marston M, Wringe A, Eaton J, Gourlay A, Rice B, Kabudula C, Urassa M, Todd J, Żaba B. Non-disclosure of HIV testing history in population-based surveys: implications for estimating a UNAIDS 90-90-90 target. Global Health Action 2018, 11: 1553470. PMCID: PMC6300092, DOI: 10.1080/16549716.2018.1553470.Peer-Reviewed Original ResearchHIV testing historyTesting historyUNAIDS 90Average HIV prevalenceEquation logistic regression modelsProportion of PLHIVRetrospective cohort studyPopulation-based surveyHIV/AIDS programsLogistic regression modelsProportion of peopleHIV-negativeClinical characteristicsCohort studyHIV testingHIV-positiveHIV statusHIV prevalenceHIVSerological surveyTreatment programSerological surveillanceAIDS ProgramNumber of participantsSurveillance system